DEFA14A: BriaCell Therapeutics Reschedules 2025 Annual General Meeting Due to Postal Delays

BriaCell Therapeutics Corp. has rescheduled its 2025 Annual General Meeting of Shareholders to February 5, 2025, due to postal service disruptions and to allow more time for proxy solicitation.

Summary

• BriaCell Therapeutics Corp. has rescheduled its 2025 Annual General Meeting of Shareholders from January 23, 2025, to February 5, 2025.
• The meeting will still be held at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4, at 9:00 a.m. Eastern Time.
• The record date for the meeting remains December 9, 2024.
• The rescheduling is due to delays stemming from postal service disruptions in Canada and to provide more time to solicit proxies.
• Shareholders who have already voted do not need to take any action unless they wish to change their vote.
• The company urges shareholders who have not yet voted to do so before the rescheduled meeting.
• Completed proxies must be received by Computershare by 9:00 a.m. Eastern Time on February 3, 2025.
• The company's proxy statement was filed on December 17, 2024, and is available on EDGAR, SEDAR+, and the company's website.
• The company has engaged Morrow Sodali (Canada) Ltd. for proxy solicitation services, paying them a fee of $25,000 plus additional fees and expenses.
• The meeting will address the receipt of audited financial statements, election of directors, and appointment of the auditor.
• The Board of Directors unanimously recommends voting FOR the proposals identified in the proxy statement.
• Institutional Shareholder Services Inc. also recommends voting FOR the proposals.
• Shareholders can vote online, by telephone, or by contacting Computershare or Sodali for assistance.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily conveys procedural information about a rescheduled meeting. The delay is a minor negative, but the company is taking steps to address it.

Positives

• Institutional Shareholder Services Inc. recommends that shareholders vote FOR the proposals.

Negatives

• The Annual General Meeting was rescheduled due to delays stemming from the disruption in postal service in Canada.

Risks

• Postal service disruptions in Canada caused delays in proxy solicitation.
• Failure to receive proxies in a timely manner could impact the outcome of the shareholder vote.

Future Outlook

The document does not contain specific forward-looking financial statements or guidance, but it outlines the matters to be addressed at the upcoming Annual General Meeting, including the election of directors and appointment of the auditor.

Management Comments

• The Companys Board of Directors unanimously recommends that you vote FOR the proposals identified in the Companys proxy statement for the Meeting.

Industry Context

The rescheduling of the meeting due to postal delays highlights the challenges companies face in ensuring timely communication with shareholders, especially in regulated industries. Proxy solicitation firms like Morrow Sodali play a crucial role in these situations.

Comparison to Industry Standards

• Engaging a proxy solicitation firm like Morrow Sodali for a fee of $25,000 plus expenses is a standard practice for companies seeking to ensure adequate shareholder representation at annual meetings.
• The use of online voting platforms and toll-free numbers for shareholder assistance aligns with industry best practices for facilitating shareholder participation.

Stakeholder Impact

• Shareholders are impacted by the rescheduled meeting and are urged to vote their shares.
• The company's management and employees are involved in the proxy solicitation process.

Next Steps

• Shareholders are urged to vote their shares before the rescheduled meeting on February 5, 2025.
• The company will hold the Annual General Meeting on February 5, 2025, to address the listed agenda items.

Key Dates

Keywords

Annual General Meeting, Proxy Statement, Shareholders, BriaCell Therapeutics, Rescheduled Meeting, Proxy Solicitation, Voting, Morrow Sodali